Abstract
Rationale
The serotonin transporter (5HTT) regulates the magnitude and duration of serotonergic neurotransmission. Although nicotine and other constituents of tobacco smoke may influence serotonin turnover among animals, few studies have examined whether smoking is associated with alteration in 5HTT in humans.
Objective
We investigated whether tobacco smokers and non-smokers differed in platelet tritiated paroxetine binding, a measure of 5HTT sites, and whether severity of nicotine dependence (ND) was related to 5HTT measures.
Methods
Tritiated paroxetine binding sites on platelets were assayed in 26 African-American smokers and 30 non-smokers. Severity of smoking was assessed using the Fagerstrom Test for Nicotine Dependence (FTND). Relationships between FTND scores and maximum number of transporter sites (Bmax) and affinity constant (Kd) of paroxetine binding were determined.
Results
Bmax values showed a significant negative correlation with FTND scores (rho=−0.28, P<0.01). Notably, smokers with higher ND had significantly lower Bmax compared to those with lower ND and non-smokers; the latter two groups did not differ in Bmax (F=3.92, P<0.05). Smokers scored higher on impulsivity than non-smokers, however, behavioral variables did not influence the relationship of smoking with Bmax. Age, gender and Kd values were not associated with smoking or Bmax.
Conclusions
Smoking, in particular higher nicotine dependence, appears to be correlated with decreased density of platelet 5HTT sites in African-Americans. The nature of the relationship and whether similar changes occur in the brain merit further investigation.
Similar content being viewed by others
References
Anthenelli RM, Maxwell RA (2000) Cigarette smoking decreases the prolactin response to serotonergic stimulation in subgroups of alcoholics and controls. Alcohol Clin Exp Res 24:987–995
Arinami T, Obtsuki T, Yamakawa-Kobayashi K, Amemiya H, Fujiwars H, Kawata KI, Ishiguro H, Hamaguchi H (1999) A synergistic effect of serotonin transporter gene polymorphism and smoking in association with CHD. Thromb Haemost 81:853–856
Beck AT, Steer RA (1987) Beck Depression Inventory. Psychological Corporation, Harcourt, Brace, Jovanovich, San Antonio, Texas
Benwell M, Balfour D (1982) Effects of nicotine administration on the uptake and biosynthesis of 5-HT in rat brain synaptosomes. Eur J Pharmacol 84:71–77
Berlin I, Said S, Spreux-Varoquaux O, Olivare R, Launay JM, Puech AJ (1995) Monoamine oxidase A and B activities in heavy smokers. Biol Psychiatry 38:756–61
Blakely RD, Ramamoorthy S, Qian Y, Schroeter S, Bradley CC (1997) Regulation of antidepressant-sensitive serotonin transporters. In: Reith MEA (ed) Neurotransmitter transporters: structure, function, and regulation. Humana Press, New Jersey, pp 29–72
Buss AH, Durkee A (1957) An inventory for assessing different kinds of hostility. J Consult Psychol 21:343–348
Buydens-Branchey L, Branchey M, Fergeson P, Hudson J, McKernin C (1997) The meta-chlorophenylpiperazine challenge test in cocaine addicts: hormonal and psychological responses. Biol Psychiatry 41:1071–1086
Castrigiovanni P, DiMuro A, Marazzati D (1995) Imipramine binding as a predictor of fluoxetine response in depressed patients. Neuropsychobiology 31:64–67
Coccaro EF, Kavoussi RJ, Sheline YL, Lish JD, Csernansky JG (1996) Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Arch Gen Psychiatry 53:531–536
Corash L, Costa JL, Shafer B, Donlon JA, Murphy D (1984) Heterogeneity of human whole blood platelet subpopulations. III. Density-dependent differences in subcellular constituents. Blood 64:185–193
Covey LS, Glassman AH, Stetner F, Rivelli S, Stage K (2002) A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am J Psychiatry 159:1731–1737
Dani JA, Heinemann S (1996) Molecular and cellular aspects of nicotine abuse. Neuron 16:905–908
Da Prada M, Cesura AM, Launay JM, Richards JG (1988) Platelets as models for neurons? Experientia 44:115–126
Etter JF, Perneger TV (2001) Measurement of self reported active exposure to cigarette smoke. J Epidemiol Commun Health 55:674–680
Etter JF, Duc TV, Perneger TV (1999) Validity of the Fagerstrom test for nicotine dependence and of the Heaviness of Smoking Index among relatively light smokers. Addiction 94:269–281
Fagerstrom KO (1978) Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 2:235–241
First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured Clinical Interview for DSM-IV disorders (SCID-IV). American Psychiatric Association, Washington D.C.
Fowler J, Volkow N, Wang G, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf A, Warner D, Zezulkova I, Cilento R (1996) Inhibition of monoamine oxidase in the brains of smokers. Nature 379:733–736
Graham D, Langer SZ (1992) Advances in sodium-ion coupled biogenic amine transporters. Life Sci 51:631–645
Greenberg BD, Tolliver TJ, Huang S, Li Q, Bengel D, Murphy DL (1999) Genetic variation in the serotonin transporter region affects serotonin uptake in human blood platelets. Am J Med Genet 88:83–87
Harrison AA, Liem YT, Markou A (2001) Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 25:55–71
Heatherton TF, Kozlowski LT, Frecker RC (1991) The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86:1119–1127
Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66:2621–2624
Hitsman B, Pingitore R, Spring B, Mahableshwarkar A, Mizes JS, Seagraves KA, Kristeller JL, Xu W (1999) Antidepressant pharmacotherapy may help some cigarette smokers more than others. J Consult Clin Psychol 67:547–554
Ishikawa H, Ohtsuki T, Ishiguro H, Yamakawa-Kobayashi K, Endo K, Lin Y, Yanagi H, Tsuchiya S, Kawata K, Hamaguchi H, Arinami T (1999) Association between serotonin transporter gene polymorphism and smoking among Japanese males. Cancer Epidemiol Biomarkers Prev 8:831–833
Killen JD, Fortmann SP, Stephen P, Schatzberg AF, Hayward C, Sussman L, Rothman M, Strusberg L, Varady A (2000) Nicotine patch and paroxetine for smoking cessation [article]. J Consult Clin Psychol 68:883–889
Lesch KP, Wolozin BL, Murphy DL, Reiderer P (1993) Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 60:2319–2322
Linnoila VM, Virkunnen M (1992) Aggression, suicidality, and serotonin. J Clin Psychiatry 53:46–51
Lowry O, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Macedo T, Ribeiro CA, Cotrim D, Tavares P, Morgadinho MT, Caramona M, Vicente MT, Rodriques L, Cardoso MG, Keating ML (1995) Catecholamine and MHPG plasma levels, platelet levels, platelet MAO activity, and 3H-imipramine binding in heroin and cocaine addicts. Mol Neurobiol 11:21–29
Maguire K, Tuckwell V, Pererira A, Dean B, Singh B (1993) Significant correlation between 14C-5-HT uptake and 3H-paroxetine binding to platelets from healthy volunteers. Biol Psychiatry 34:356–360
Maguire KP, Norman TR, Apostolopoulos M, Judd FK, Burrows GD (1995) Platelet [3H] paroxetine binding in panic disorder. J Affect Disord 33:117–122
Mendez-Alvarez E, Soto-Otero R, Sanchez-Sellero I, Lopez-Rivadulla M, Lamas M (1997) Inhibition of brain monoamine oxidase activity by adducts of 1,2,3,4-tetraishydroisoquinoline with components of cigarette smoke. Life Sci 60:1719–1727
Niaura R, Spring B, Borrelli B, Hedeker D, Goldstein MG, Keuthen N, Depue J, Kristeller J, Ockene J, Prochazka A, Chiles JA, Abrams DB (2002). Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J Consult Clin Psychol 70:887–896
Olausson P, Engel JA, Soderpalm B (2002) Involvement of serotonin in nicotine dependence: processes relevant to positive and negative regulation of drug intake. Pharmacol Biochem Behav 71:757–771
Ozaki N, Rosenthal NE, Mazzola P, Chiveh CC, Hardin T, Garcia-Borreguero D, Schwartz PJ, Turner E, Oren DA, Murphy DL (1994) Platelet [3H]paroxetine binding, 5-HT stimulated Ca2+ response, and 5-HT content in winter seasonal affective disorder. Biol Psychiatry 136:458–466
Patkar AA, Naik P, Mardsen CA, McLean PC, Kendall DA, Al-Chalabi T (1995) Platelet [3H]-binding in type I and type II alcoholism. Hum Psychopharmacol 10:1–6
Patkar AA, Gottheil E, Berrettini WH, Hill KP, Thornton CC, Weinstein SP (2003) Relationship between platelet serotonin uptake sites and measures of impulsivity, aggression and craving among African-American cocaine abusers. Am J Addict (in press)
Pomerleau CS, Pomerleau OF, Majchrzak MJ, Kloska DD, Malakuti R (1990) Relationship between nicotine tolerance questionnaire scores and plasma cotinine. Addict Behav 15:73–80
Rausch JL, Fefferman M, Ladisich-Rogers DG, Menard M (1989) Effect of nicotine on human blood platelet serotonin uptake and efflux. Prog Neuropsychopharmacol Biol Psychiatry 13:907–916
Reuben M, Clarke PB (2000) Nicotine-evoked [3H]5-hydroxytryptamine release from rat striatal synaptosomes. Neuropharmacology 39:290–299
Ribeiro EB, Bettiker RL, Bogdanov M, Wurtman RJ (1993) Effects of systemic nicotine on serotonin release in rat brain. Brain Res 621:311–318
Seth P, Cheeta S, Tucci S, File SE (2002) Nicotinic -serotonergic interactions in brain and behavior. Pharmacol Biochem Behav 71:795–805
Sheline YI, Black KJ, Bardgett ME, Csernansky JG (1005) Platelet binding characteristics distinguish placebo responders from nonresponders. Neuropsychopharmacology 12:315–322
Strachan AT, Maughan RJ (1998) Platelet serotonin transporter density and related parameters in endurance trained and sedentary male subjects. Acta Physiol Scand 163:165–171
Wagenknecht LE, Cutter GR, Haley NJ, Sidney S, Manolio TA, Hughes GH, Jacobs DR (1990) Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. Am J Public Health 80:1053–1056
Xu Z, Seidler FJ, All SF, Slikker W, Slotkin TA (2001) Fetal and adolescent nicotine administration: effects on CNS. Brain Res 914:166–178
Acknowledgements
This research was supported by grant KO8DA00340-02 from the National Institute on Drug Abuse and performed under the auspices of the Commonwealth Office of Drug and Alcohol Programs and the Philadelphia Department of Public Health, Coordinating Bureau for Drug and Alcohol Abuse Programs. We appreciate the contributions of Cheryl Marshall, Heather Murray and Allan Lundy in data collection and analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Patkar, A.A., Gopalakrishnan, R., Berrettini, W.H. et al. Differences in platelet serotonin transporter sites between African-American tobacco smokers and non-smokers. Psychopharmacology 166, 221–227 (2003). https://doi.org/10.1007/s00213-002-1353-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-002-1353-2